These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 38234016)
1. Computational insights into overcoming resistance mechanisms in targeted therapies for advanced breast cancer: focus on EGFR and HER2 co-inhibition. Abdulaziz O; Khan FR; Alharthi NS; Alhuthali HM; Hazazi A; Alzahrani HA; Gharib AF; Alsalmi OA; Hawsawi NM; Alhazmi AY J Biomol Struct Dyn; 2024 Jan; ():1-12. PubMed ID: 38234016 [TBL] [Abstract][Full Text] [Related]
2. Computational analysis of bevacizumab binding with protein receptors for its potential anticancer activity. Alsakhen N; Radwan ES; Zafer I; Abed Alfattah H; Shamkh IM; Rehman MT; Shahwan M; Khan KA; Ahmed SA J Biomol Struct Dyn; 2024 Jan; ():1-21. PubMed ID: 38281913 [TBL] [Abstract][Full Text] [Related]
3. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents. Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701 [TBL] [Abstract][Full Text] [Related]
4. Dual functionality of pyrimidine and flavone in targeting genomic variants of EGFR and ER receptors to influence the differential survival rates in breast cancer patients. Avti PK; Singh J; Dahiya D; Khanduja KL Integr Biol (Camb); 2023 Apr; 15():. PubMed ID: 38084900 [TBL] [Abstract][Full Text] [Related]
6. Identification of HER2 inhibitors from curcumin derivatives using combination of Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338 [TBL] [Abstract][Full Text] [Related]
7. Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319 [TBL] [Abstract][Full Text] [Related]
8. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells. Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094 [TBL] [Abstract][Full Text] [Related]
9. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Hartman Z; Zhao H; Agazie YM Oncogene; 2013 Aug; 32(35):4169-80. PubMed ID: 23027125 [TBL] [Abstract][Full Text] [Related]
10. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395 [TBL] [Abstract][Full Text] [Related]
12. Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies. Rehman ZU; Najmi A J Biomol Struct Dyn; 2023 Sep; ():1-21. PubMed ID: 37707987 [TBL] [Abstract][Full Text] [Related]
13. Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer. Siddiqui AJ; Jahan S; Patel M; Abdelgadir A; Alturaiki W; Bardakci F; Sachidanandan M; Badraoui R; Snoussi M; Adnan M J Biomol Struct Dyn; 2023; 41(23):14460-14472. PubMed ID: 36826428 [TBL] [Abstract][Full Text] [Related]
14. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach. Agarwal S; Kashaw SK J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712 [TBL] [Abstract][Full Text] [Related]
16. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies. Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960 [TBL] [Abstract][Full Text] [Related]
17. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). Hartman Z; Geldenhuys WJ; Agazie YM J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694 [TBL] [Abstract][Full Text] [Related]
18. Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2. Balbuena-Rebolledo I; Padilla-Martínez II; Rosales-Hernández MC; Bello M Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451888 [TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report. Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069 [TBL] [Abstract][Full Text] [Related]
20. In silico target specific design of potential quinazoline-based anti-NSCLC agents. Mohammadnejadi E; Razzaghi-Asl N J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]